Indeed we find that the majority of patients (13 out of 15) in cluster 3 with a high SBS9 contribution (≥10%) had already received prior treatment, although this did not reach statistical significance (Fisher’s exact test p = 0.07).
← all excerpts
Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features.
1
0.0700
0.0700